Literature DB >> 19925953

Poxvirus-vectored vaccines for rabies--a review.

Jacqueline Weyer1, Charles E Rupprecht, Louis H Nel.   

Abstract

Oral rabies vaccination of target reservoir species has proved to be one of the pillars of successful rabies elimination programs. The use of live attenuated rabies virus vaccines has been extensive but several limitations hamper its future use. A recombinant vaccinia-rabies vaccine has also been successfully used for the oral vaccination of several species. Nevertheless, its lack of efficacy in certain important rabies reservoirs and concerns on the use of this potent live virus as vaccine carrier (vector) impair the expansion of its use for new target species and new areas. Several attenuated and host-restricted poxvirus alternatives, which supposedly offer enhanced safety, have been investigated. Once again, efficacy in certain target species and innocuity through the oral route remain major limitations of these vaccines. Alternative recombinant vaccines using adenovirus as an antigen delivery vector have been extensively investigated and may provide an important addition to the currently available oral rabies vaccine repertoire, but are not the primary subject of this review.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19925953     DOI: 10.1016/j.vaccine.2009.09.033

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  16 in total

Review 1.  Experimental rabies vaccines for humans.

Authors:  James P McGettigan
Journal:  Expert Rev Vaccines       Date:  2010-10       Impact factor: 5.217

2.  Coupling mutagenesis and parallel deep sequencing to probe essential residues in a genome or gene.

Authors:  William P Robins; Shah M Faruque; John J Mekalanos
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-11       Impact factor: 11.205

3.  Rabies virus (RV) glycoprotein expression levels are not critical for pathogenicity of RV.

Authors:  Christoph Wirblich; Matthias J Schnell
Journal:  J Virol       Date:  2010-11-10       Impact factor: 5.103

4.  A novel rabies vaccine based on a recombinant parainfluenza virus 5 expressing rabies virus glycoprotein.

Authors:  Zhenhai Chen; Ming Zhou; Xiudan Gao; Guoqing Zhang; Guiping Ren; Clement W Gnanadurai; Zhen F Fu; Biao He
Journal:  J Virol       Date:  2012-12-26       Impact factor: 5.103

5.  Short communication: a modified Vaccinia virus Ankara-based Porcine circovirus 2 vaccine elicits strong antibody response upon prime-boost homologous immunization in a preclinical model.

Authors:  Danielle Soares de Oliveira Daian E Silva; Edel Figueiredo Barbosa-Stancioli; Jordana Graziela Alves Coelho-Dos-Reis; Flávio Guimarães Da Fonseca
Journal:  Braz J Microbiol       Date:  2020-03-06       Impact factor: 2.476

6.  A new rabies vaccine based on a recombinant ORF virus (parapoxvirus) expressing the rabies virus glycoprotein.

Authors:  Ralf Amann; Jörg Rohde; Ulrich Wulle; Douglas Conlee; Rudiger Raue; Olivier Martinon; Hanns-Joachim Rziha
Journal:  J Virol       Date:  2012-11-21       Impact factor: 5.103

7.  A novel high-throughput vaccinia virus neutralization assay and preexisting immunity in populations from different geographic regions in China.

Authors:  Qiang Liu; Weijin Huang; Jianhui Nie; Rong Zhu; Dongying Gao; Aijing Song; Shufang Meng; Xuemei Xu; Youchun Wang
Journal:  PLoS One       Date:  2012-03-16       Impact factor: 3.240

8.  The present and future of rabies vaccine in animals.

Authors:  Dong-Kun Yang; Ha-Hyun Kim; Kyung-Woo Lee; Jae-Young Song
Journal:  Clin Exp Vaccine Res       Date:  2013-01-15

Review 9.  Pre-existing immunity against vaccine vectors--friend or foe?

Authors:  Manvendra Saxena; Thi Thu Hao Van; Fiona J Baird; Peter J Coloe; Peter M Smooker
Journal:  Microbiology       Date:  2012-11-22       Impact factor: 2.777

Review 10.  Emerging Vaccine Technologies.

Authors:  Rebecca J Loomis; Philip R Johnson
Journal:  Vaccines (Basel)       Date:  2015-05-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.